Multi-Disciplinary Organization Dedicated to Promoting Advances in
Neuro-Oncology Through Research and Education

WFNOS Magazine

The inaugural issue of the official publication of the World Federation of Neuro-Oncology Societies is ...

Read Full Story

Neuro-Oncology Review Course at SNO

November 16, 2016. Register in conjunction with the SNO Annual Meeting

Read Full Story

CNS Anticancer Drug Discovery and Development Conference

Register Now!

Read Full Story
View All News


EANO 2016

Read Full Story


18th Annual Brain Tumor Update and 7th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine

Read Full Story


2nd CNS Anticancer Drug Discovery/Development Conference

Read Full Story

CNS Anticancer Drug Discovery/Development Conference

November 12 - 13, 2014, Loews Hotel, Miami Beach, FL
This special two day conference will focus on the range of issues that have impacted the failure to develop unique drugs for CNS cancers as well as innovative approaches being applied to brain tumor chemotherapy.  Through this educational and research-oriented conference, the committee hopes to create a dialogue amongst attendees and their collaborators to enhance drug development for primary gliomas (pediatric and adult) and tumors that metastasize to the CNS and, thereby, improve patient outcomes.
The Committee thanks the following for generous support:
     Bristol-Myers Squibb
To register (space is limited) click here.
To reserve a room at the preferred SNO rate (limited availability) click here.
The Program Committee has developed a program of invited speakers and panel discussions and will accept abstracts focused on the following topics:
• Strategies to identify new druggable targets
• Therapeutic impact of irreversible versus reversible inhibitors
• Therapeutic impact of selective versus multi-targeted agents
• Barriers to CNS drug distribution
• Pharmacokinetics of brain tumor drugs
• Importance of tumor heterogeneity
• Pharmacodynamics and systems pharmacology
• Personalizing therapy
• Regulatory paths for cytostatic and multi-agent therapy approval
• Regulatory paths for low- and mid-grade CNS tumor agents
• Regulatory and clinical relevance of PFS, OS, and stable disease
Speakers accepting invitation to speak at the conference include:
  • Donald Berry, PhD, University of Texas M.D. Anderson Cancer Center
  • Marc Birtwistle, PhD, Icahn School of Medicine at Mount Sinai, Pharmacology and Systems Therapeutics
  • Arvin Dar, PhD,  Icahn School of Medicine at Mount Sinai, Department of Oncological Sciences
  • William Elmquist, PhD, University Minnesota School of Pharmacy, Department of Pharmaceutics
  • Timothy Heffron, PhD, Discovery Chemistry, Genentech, Inc.
  • Antonio Iavarone, MD, Columbia University Institute for Cancer Genetics
  • Jean E. Lachowicz, PhD,  Angiochem, Inc.
  • Victor Levin, MD, Emeritus, University of Texas M.D. Anderson Cancer Center and UCSF Medical School
  • James Olson, MD, PhD, University of Washington Fred Hutchinson Cancer Research Center and Presage Biosciences
  • Wang Shen, PhD, Kanion USA, Inc
  • Quentin Smith, PhD, Texas Tech University School of Pharmacy
  • Joohee Sul, MD, United States Federal Drug Administration
  • Peter Tonge, MD, PhD, Stony Brook University
  • Patrick Wen, MD, Dana-Farber Cancer Institute, Harvard University
  • Forest White, PhD,  Massachusetts Institute of Technology, Department of Biological Engineering
Victor A. Levin, MD, Clinical Professor, Department of Neurosurgery, UCSF; Emeritus Professor, Department of Neuro-Oncology, UT M.D. Anderson Cancer Center
Stephen L. Eck, MD, PhD, Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development
William Elmquist, PhD, Chair, Department of Pharmaceutics, University of Minnesota
James M. Gallo, PhD, Professor, Dept. of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai
Timothy Heffron, PhD, Senior Scientist, Discovery Chemistry, Genentech Research
Alan Olivero, PhD, Senior Director, Discovery Chemistry, Genentech Research and Early Development
Jann Sarkaria, MD, Associate Professor, Department of Radiation Oncology, Mayo Clinic
Beverly Teicher, PhD, Chief, Molecular Pharmacology Branch, National Cancer Institute
Questions? Contact Linda Greer,  281-554-6589